يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
NeuroPace Presented Data From Long-Term Post-Approval Study Of RNS System On Apr. 7; Says Long-Term Seizure Reduction With A Median Reduction Of 82% At 3 Years
NEUROPACE, INC. -1.00% Post
NEUROPACE, INC. NPCE | 0.00 |
- Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1
- Long-term seizure reduction with a median reduction of 82% at 3 years.
- Seizure freedom with 42% of patients remaining seizure free for 6+ months.i